Principal Financial Group Inc Rubius Therapeutics, Inc. Transaction History

Principal Financial Group Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$0.46 - $1.29 $142 - $399	310 Added 3.07%	10,417 $5,000
Q2 2022 Aug 10, 2022	SELL	$0.79 - $5.98 $55 - $418	-70 Reduced 0.69%	10,107 $9,000
Q1 2022 May 09, 2022	SELL	$4.25 - $10.4 $2,431 - $5,948	-572 Reduced 5.32%	10,177 $56,000
Q4 2021 Feb 09, 2022	SELL	$9.68 - $17.74 $52,088 - $95,458	-5,381 Reduced 33.36%	10,749 $104,000
Q3 2021 Nov 09, 2021	SELL	$17.6 - $25.91 $45,953 - $67,651	-2,611 Reduced 13.93%	16,130 $288,000
Q2 2021 Aug 10, 2021	BUY	$22.26 - $28.43 $417,174 - $532,806	18,741 New	18,741 $457,000
Q4 2020 Feb 08, 2021	SELL	$4.23 - $8.73 $68,678 - $141,740	-16,236 Closed	0 $0
Q3 2020 Nov 06, 2020	SELL	$4.65 - $6.25 $3,738 - $5,025	-804 Reduced 4.72%	16,236 $81,000
Q2 2020 Aug 05, 2020	BUY	$4.01 - $6.88 $21,706 - $37,241	5,413 Added 46.56%	17,040 $102,000
Q4 2019 Feb 05, 2020	SELL	$7.23 - $14.12 $990 - $1,934	-137 Reduced 1.16%	11,627 $110,000
Q3 2019 Nov 13, 2019	SELL	$7.85 - $15.75 $2,983 - $5,985	-380 Reduced 3.13%	11,764 $92,000
Q2 2019 Aug 12, 2019	BUY	$13.5 - $19.94 $163,944 - $242,151	12,144 New	12,144 $191,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.